Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
Zacks Investment Research9/7/2026Negative
IONS
Ionis Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.65B
P/E Ratio
—
EPS
$-3.48
Beta
0.42
52W High
$86.74
52W Low
$50.01
50-Day MA
$61.24
200-Day MA
$73.42
Dividend Yield
—
Profit Margin
-64.70%
Forward P/E
90.91
PEG Ratio
25.70
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Fundamentals
| Revenue (TTM) | $874.09M |
| Gross Profit (TTM) | $-60.60M |
| EBITDA | $-579.48M |
| Operating Margin | -38.20% |
| Return on Equity | -105.50% |
| Return on Assets | -12.40% |
| Revenue/Share (TTM) | $5.36 |
| Book Value | $2.65 |
| Price-to-Book | 21.97 |
| Price-to-Sales (TTM) | 11.04 |
| EV/Revenue | 10.55 |
| EV/EBITDA | 135.77 |
| Quarterly Earnings Growth (YoY) | -43.70% |
| Quarterly Revenue Growth (YoY) | -40.70% |
| Shares Outstanding | $166.18M |
| Float | $164.82M |
| % Insiders | 0.61% |
| % Institutions | 110.57% |
Historical Volatility
HV 10-Day
42.03%
HV 20-Day
38.07%
HV 30-Day
38.62%
HV 60-Day
68.90%
HV Rank
76.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($88.00 target)
9
Strong Buy10
Buy5
HoldLatest News
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Zacks Investment Research9/7/2026Negative
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
Reuters9/4/2026Negative
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
Seeking Alpha9/4/2026Neutral
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
Ionis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.
MarketBeat9/4/2026Positive
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
Zacks Investment Research9/4/2026Positive
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic and gastrointestinal function. Until now, treatment of AxD has.
Business Wire9/3/2026Neutral
US FDA approves Ionis Pharma's therapy to treat rare brain disorder
The U.S. FDA on Thursday approved Ionis Pharmaceuticals' therapy to treat a rare disease that affects the brain's white matter, making it the first treatment to get the nod for the genetic disorder.
Reuters9/3/2026Positive
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research8/28/2026Positive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire8/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IONS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026